Early rhythm control in atrial fibrillation with tricuspid regurgitation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares early rhythm control strategies—such as anti-arrhythmic drugs, DC cardioversion, and catheter ablation—with usual care in patients who have both atrial fibrillation and tricuspid regurgitation. The goal is to see if early rhythm control reduces a composite outcome of cardiac death, heart failure hospitalization, stroke, or need for tricuspid valve surgery. The analysis will explore how early rhythm control influences right heart remodeling and clinical events over time. The results may help determine if early rhythm control should be considered in this patient population. The study is conducted at Samsung Medical Center in Seoul, with Samsung as the lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with concomitant atrial fibrillation and tricuspid regurgitation.

Exclusion Criteria:

* Patients with a history of valvular surgery
* Patients with congenital heart disease
* Patients with primary pulmonary hypertension
* Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation
* Patients diagnosed with TR only after the initiation of rhythm control therapy for AF

Where it's running

• Samsung Medical Center
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Ju Youn Kim, Ph.D
• Email: kzzoo921@gmail.com
• Phone: 82+ 10-5482-7307

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• What happens to the tricuspid valve in atrial fibrillation patients without strong valve leakage

  This study looks at how the tricuspid valve changes over a year in people with atrial fibrillation who don’t have significant valve leakage, using 3D heart imaging.

  Recruiting Centro Cardiologico Monzino · Milan, Milan · NCT07617974

• Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation

  This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.

  Recruiting St. Josefs-Hospital Wiesbaden GmbH · Wiesbaden · NCT07910370

• Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation

  This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.

  Recruiting East Sussex Healthcare NHS Trust · Eastbourne · NCT07900685

• Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF

  This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07874763

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes

  This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.

  Recruiting at 5 sites Insel Gruppe AG, University Hospital Bern · Zabrze and 4 other locations · NCT07852221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.